528 related articles for article (PubMed ID: 23439744)
21. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
22. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
[TBL] [Abstract][Full Text] [Related]
24. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
[TBL] [Abstract][Full Text] [Related]
25. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
Ellis SL; Moser EG; Snell-Bergeon JK; Rodionova AS; Hazenfield RM; Garg SK
Diabet Med; 2011 Oct; 28(10):1176-81. PubMed ID: 21923696
[TBL] [Abstract][Full Text] [Related]
26. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
28. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
[TBL] [Abstract][Full Text] [Related]
30. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Raz I; Hanefeld M; Xu L; Caria C; Williams-Herman D; Khatami H;
Diabetologia; 2006 Nov; 49(11):2564-71. PubMed ID: 17001471
[TBL] [Abstract][Full Text] [Related]
32. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
Williams-Herman D; Johnson J; Teng R; Golm G; Kaufman KD; Goldstein BJ; Amatruda JM
Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
[TBL] [Abstract][Full Text] [Related]
34. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
35. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
[TBL] [Abstract][Full Text] [Related]
37. Janumet: a combination product suitable for use in patients with Type 2 diabetes.
Reynolds JK; Neumiller JJ; Campbell RK
Expert Opin Investig Drugs; 2008 Oct; 17(10):1559-65. PubMed ID: 18808315
[TBL] [Abstract][Full Text] [Related]
38. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Plosker GL
Drugs; 2014 Feb; 74(2):223-42. PubMed ID: 24407560
[TBL] [Abstract][Full Text] [Related]
39. [Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
Ametov AS; Gusenbekova DG
Ter Arkh; 2014; 86(8):85-9. PubMed ID: 25306750
[TBL] [Abstract][Full Text] [Related]
40. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
